Revelation Biosciences, Inc. (REVB)

NASDAQ: REVB · Real-Time Price · USD
0.8700
+0.0960 (12.40%)
At close: Jun 24, 2025, 4:00 PM
0.8500
-0.0200 (-2.30%)
After-hours: Jun 24, 2025, 7:59 PM EDT
12.40%
Market Cap 1.77M
Revenue (ttm) n/a
Net Income (ttm) -14.41M
Shares Out 2.03M
EPS (ttm) -36.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 537,619
Open 0.7700
Previous Close 0.7740
Day's Range 0.7700 - 0.8784
52-Week Range 0.7425 - 60.8000
Beta -0.09
Analysts n/a
Price Target n/a
Earnings Date Aug 8, 2025

About REVB

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in Janua... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 9
Stock Exchange NASDAQ
Ticker Symbol REVB
Full Company Profile

Financial Performance

Financial Statements

News

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

26 days ago - Business Wire

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

26 days ago - Business Wire

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

4 weeks ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...

6 weeks ago - Business Wire

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

2 months ago - Business Wire

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

3 months ago - Business Wire

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

3 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...

3 months ago - Business Wire

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

4 months ago - Business Wire

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...

4 months ago - Business Wire

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-...

5 months ago - Business Wire

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

5 months ago - Business Wire

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the powe...

5 months ago - Business Wire

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the powe...

6 months ago - Business Wire

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

SAN DIEGO--(BUSINESS WIRE)---- $REVB #REVB--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power ...

7 months ago - Business Wire

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

7 months ago - Business Wire

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of tr...

8 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power ...

8 months ago - Business Wire

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

9 months ago - Business Wire

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immuni...

10 months ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of tr...

11 months ago - Business Wire

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

1 year ago - Business Wire

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

1 year ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

1 year ago - Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023

SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...

1 year ago - Business Wire